

Newly Redesigned Confirm mdx Patient Report

Launching Monday, November 10, 2025

We are excited to present our updated patient report design, reflecting our commitment to clear, actionable results.

IMPORTANT: The Confirm mdx test is unchanged – only the report format has been updated.

Previous Confirm mdx Patient Report

SAMPLE Patient Report

PATIENT
Patient Name: John Sample
Date of Birth: 01/01/1942
MRN/External ID: 123456
PHN: 949.123.4567
DOB: 01/01/1942
City/State: Irvine, CA 92618

SPECIMEN
Specimen ID: 5641305
Collection Date: 08/22/2024
Report Date: 09/23/2024
Specimen Type: FFPE tissue slides
MDX Accession #: P15-123456

ACCOUNT
Physician: John Sample, MD
Address: 16270 Alton Parkway, STE 100
City/State: Irvine, CA 92618

Patient Result: DNA Methylation Positive
The DNA methylation positive test result for this patient indicates a 32% likelihood of detecting prostate cancer, with a 20% probability for low-grade disease (GS ≤ 6) versus a 12% probability of high-grade disease (GS ≥ 7), on repeat biopsy.

Likelihood of prostate cancer upon repeat biopsy
0% 20% 32% 100%
Likelihood of detecting Gleason score ≤ 6 cancer: 20%
Likelihood of detecting Gleason score ≥ 7 cancer: 12%

The ConfirmMDx test result indicating the likelihood of GS ≤ 6 and GS ≥ 7 prostate cancer being detected on repeat biopsy is calculated by incorporating DNA methylation intensity with clinical risk factors, including PSA, DRE, age, and histopathology of the previous biopsy, based on a validated model that yields an overall AUROC of 0.702 (95% CI: 0.673-0.734). Performance is based on the presence of all relevant data elements; if all data are not available, or low-dose/short-term biopsies (LDBT) have been administered to decrease serum PSA values, results should be interpreted with caution since the AUROC of the test may vary. Cancer association with DNA methylation of the ConfirmMDx gene markers has been reported on ~4,500 patients.^{1,2}

DNA Methylation Status Table

| Biopsy Site | GS/PSI Methylation | APC Methylation | MDX/PSI Methylation |
|-----------------------|--------------------|-----------------|---------------------|
| Left Lateral Base | Negative | Negative | Negative |
| Left Lateral Mid | Negative | Negative | Negative |
| Left Lateral Apex | Negative | Negative | Negative |
| Left Base | Negative | Negative | Negative |
| Left Mid | Positive | Positive | Positive |
| Left Apex | Negative | Negative | Negative |
| Left Transition Zone | Negative | Negative | Negative |
| Right Base | Negative | Negative | Negative |
| Right Mid | Negative | Negative | Negative |
| Right Apex | Negative | Negative | Negative |
| Right Transition Zone | Negative | Negative | Negative |
| Right Lateral Base | Negative | Negative | Negative |
| Right Lateral Mid | Negative | Negative | Negative |
| Right Lateral Apex | Negative | Negative | Negative |
| Right Transition Zone | Negative | Negative | Negative |

Distribution of DNA Methylation Diagram
Posterior View Base
Left Right
Apex
Left Transition Zone Right Transition Zone

MDxHealth www.mdxhealth.com
MdxHealth Inc., 16270 Alton Parkway, Suite 100 | Irvine, CA 92618 | P: 866.259.5644 | F: 949.788.0014 | E: cs@mdxhealth.com • www.mdxhealth.com
© 2025 MdxHealth S.A. All rights reserved.

New Confirm mdx Patient Report

SAMPLE Patient Report

Patient
Patient Name: David Sample
Date of Birth: 12/27/1959
MDN/External ID: 8978901
Path: Negative
PSA: 9.4 ng/ml
DRE: Normal

Specimen
Specimen ID: 5641305
Collection Date: 08/22/2024
Report Date: 09/23/2024
Specimen Type: FFPE tissue slides
MDX Accession #: P15-123456

Physician
John Sample, MD
Urology Associates
16270 Alton Parkway, STE 100
Irvine, CA 92618

PATIENT RESULT: DNA METHYLATION POSITIVE
DNA Methylation Positive: This patient's test result indicates a 17% risk for Gleason Score (GS) ≥ 7 (3+4) cancer, 21% for GS 6 cancer and a 38% risk for any prostate cancer.

Likelihood of detecting GS ≥ 7 (3+4) upon repeat biopsy:
0% 17% 75% 100%

1 Risk of GS ≥ 7 (3+4) presented first and prominently

2 Enhanced methylation table and prostate diagram

3 Test description moved to page 2

21% Likelihood of detecting GS 6 cancer upon repeat biopsy

38% Likelihood of any prostate cancer upon repeat biopsy

DNA Methylation Status Table

| Biopsy Site | GS/PSI Methylation | APC Methylation | MDX/PSI Methylation |
|--------------------|--------------------|-----------------|---------------------|
| Left Lateral Base | NEG | NEG | NEG |
| Left Lateral Apex | NEG | NEG | NEG |
| Left Lateral Base | NEG | NEG | NEG |
| Left Lateral Mid | NEG | NEG | NEG |
| Left Mid | POS | POS | NEG |
| Right Apex | NEG | NEG | NEG |
| Right Base | NEG | NEG | NEG |
| Right Lateral Apex | NEG | NEG | NEG |
| Right Lateral Base | NEG | NEG | NEG |
| Right Lateral Mid | NEG | NEG | NEG |
| Right Mid | NEG | NEG | NEG |


Distribution of DNA Methylation Diagram
Left Right
Left Transition Zone Apex Right Transition Zone

Report Flag
NEG = DNA METHYLATION NEGATIVE
POS = DNA METHYLATION POSITIVE

mdxhealth
Page 1 of 2

Questions?

Email cs@mdxhealth.com or call 866.259.5644 (Mon – Fri, 5:00am-5:00pm PT)



Scan to view all report versions
or visit
mdxhealth.com/ConfirmReport

mdxhealth

Superior care made easy.

Streamline your workflow while maintaining a high level of care. Mdxhealth delivers comprehensive solutions with dedicated support.

P: 866.259.5644 • F: 949.788.0014 • E: cs@mdxhealth.com • www.mdxhealth.com

© 2025 Mdxhealth S.A. All rights reserved. IR-BROC-0243-R01

Newly Redesigned Confirm mdx Patient Report

Launching Monday, November 10, 2025

We are excited to present our updated patient report design, reflecting our commitment to clear, actionable results.

IMPORTANT: The Confirm mdx test is unchanged – only the report format has been updated.

Previous Confirm mdx Patient Report (Non-systematic biopsy)

The previous report format was more cluttered, with patient information at the top, followed by a DNA Methylation Positive result, and then a large table of biomarkers. The likelihood of detecting cancer was shown as a horizontal bar chart.


New Confirm mdx Patient Report (Non-systematic biopsy)

The new report format is cleaner and more focused. It features a patient information section, a specimen section, and a physician section. The DNA Methylation Positive result is prominently displayed. The likelihood of detecting cancer is shown as a circular progress indicator, with a 17% risk for Gleason Score (GS) ≥ 7 (3+4) cancer, 21% for GS 6 cancer, and 38% for any prostate cancer upon repeat biopsy.

- 1 Risk of GS \geq 7 (3+4) presented first and prominently
- 2 Enhanced methylation table
- 3 Test description moved to page 2

Questions?

Email cs@mdxhealth.com or call 866.259.5644 (Mon – Fri, 5:00am-5:00pm PT)



Scan to view all report versions
or visit
mdxhealth.com/ConfirmReport

mdxhealth

Superior care made easy.

Streamline your workflow while maintaining a high level of care. Mdxhealth delivers comprehensive solutions with dedicated support.

P: 866.259.5644 • F: 949.788.0014 • E: cs@mdxhealth.com • www.mdxhealth.com

© 2025 Mdxhealth S.A. All rights reserved. IR-BROC-0243-R01